{"id":15960,"date":"2020-05-20T09:12:37","date_gmt":"2020-05-20T07:12:37","guid":{"rendered":"https:\/\/asscat-hepatitis.org\/?p=15960"},"modified":"2020-05-20T09:12:37","modified_gmt":"2020-05-20T07:12:37","slug":"noves-estimacions-ressalten-la-necessitat-dintensificar-la-resposta-a-lhepatitis-d","status":"publish","type":"post","link":"https:\/\/asscat-hepatitis.org\/ca\/noves-estimacions-ressalten-la-necessitat-dintensificar-la-resposta-a-lhepatitis-d\/","title":{"rendered":"Noves estimacions ressalten la necessitat d\u2019intensificar la resposta a l\u2019hepatitis D"},"content":{"rendered":"<p>[et_pb_section bb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|off&#8221; _builder_version=&#8221;3.0.106&#8243; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;0px||0px|&#8221; next_background_color=&#8221;#000000&#8243;][et_pb_row custom_padding=&#8221;0px||0px|&#8221; _builder_version=&#8221;3.0.106&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_post_title author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; comments=&#8221;off&#8221; featured_placement=&#8221;background&#8221; text_background=&#8221;on&#8221; text_bg_color=&#8221;#ffffff&#8221; module_class=&#8221;ac-post-title-section-0&#8243; _builder_version=&#8221;3.0.106&#8243; title_font=&#8221;Montserrat|600|||||||&#8221; title_text_color=&#8221;#2d2d2d&#8221; title_letter_spacing=&#8221;-1px&#8221; title_line_height=&#8221;1.2em&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_color=&#8221;rgba(45,45,45,0.5)&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;|20px|20px|20px&#8221; title_text_align=&#8221;center&#8221; meta_font_size=&#8221;13px&#8221; meta_text_align=&#8221;center&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; specialty=&#8221;on&#8221; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;0px|||&#8221; prev_background_color=&#8221;#000000&#8243; next_background_color=&#8221;#000000&#8243;][et_pb_column type=&#8221;2_3&#8243; specialty_columns=&#8221;2&#8243;][et_pb_row_inner admin_label=&#8221;Fila&#8221; _builder_version=&#8221;3.0.106&#8243;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_text admin_label=&#8221;Contenido Entrada 1&#8243; ul_type=&#8221;square&#8221; module_class=&#8221;ac-posts-content&#8221; _builder_version=&#8221;3.0.106&#8243; text_orientation=&#8221;justified&#8221; background_layout=&#8221;light&#8221;]<\/p>\n<h3>En un estudio publicat al <em>Journal of Hepatology<\/em>, la professora Anna Maria Geretti i el Dr. Alexander Stockdale de la Universitat de Liverpool (Regne Unit), en col\u00b7laboraci\u00f3 amb investigadors de l\u2019Organitzaci\u00f3 Mundial de la Salut (OMS) i l\u2019Agencia Internacional per a la Investigaci\u00f3 del C\u00e0ncer (IARC), estimen que a tot el m\u00f3n, el virus de l\u2019hepatitis D (VHD) afecta a gaireb\u00e9 el 5% de les persones que tenen una infecci\u00f3 cr\u00f2nica amb el virus de l\u2019hepatitis B (VHB) i que la coinfecci\u00f3 per VHD podria explicar aproximadament 1 de cada 5 casos de malaltia hep\u00e0tica i c\u00e0ncer de fetge en persones amb infecci\u00f3 per VHB.<\/h3>\n<p>Per mapejar l\u2019epidemiologia de la infecci\u00f3 per VHD al m\u00f3n, la professora Geretti i el Dr. Stockdale van unir forces amb el Programa Mundial d\u2019Hepatitis de l\u2019OMS i el IARC, juntament amb investigadors a Alemanya, Malawi i el Regne Unit. <em>\u201cLa infecci\u00f3 amb VHD t\u00e9 lloc en aproximadament 1 de cada 22 casos d\u2019infecci\u00f3 cr\u00f2nica pel VHB al m\u00f3n\u201d<\/em>, explica el Dr. Stockdale. <em>\u201cEs necessiten m\u00e9s dades d\u2019alta qualitat, per\u00f2 hem identificat diversos punts cr\u00edtics geogr\u00e0fics d\u2019alta prevalen\u00e7a d\u2019infecci\u00f3 per VHD: a Mong\u00f2lia, la Rep\u00fablica de Mold\u00e0via i pa\u00efsos de l\u2019\u00c0frica occidental i mitja\u201d<\/em>.<\/p>\n<p><em>\u201cTot i que \u00e9s menys com\u00fa que l\u2019hepatitis B, l\u2019hepatitis D \u00e9s una malaltia greu que sovint afecta a poblacions desfavorides i vulnerables\u201d<\/em>, afirma la Dra. Meg Doherty, directora del Programa Mundial d\u2019Hepatitis de l\u2019OMS. Entre aquells que tenen m\u00e9s probabilitats de tenir coinfecci\u00f3 per VHB i VHD s\u2019inclouen persones que s\u2019injecten drogues i persones amb el virus de l\u2019hepatitis C o infecci\u00f3 per VIH. El risc de coinfecci\u00f3 tamb\u00e9 sembla ser major en els receptors d\u2019hemodi\u00e0lisi, els homes que tenen relacions sexuals amb homes i les treballadores sexuals comercials. El Dr. Doherty senyala: <em>\u201cAquesta informaci\u00f3 ajuda a identificar els grups amb VHB entre els quals haur\u00edem de buscar VHD\u201d<\/em>.<\/p>\n<p>El VHD (anteriorment conegut com l\u2019agent Delta) \u00e9s un virus petit, un dels m\u00e9s petits que es sap que causa malalties en els humans, i nom\u00e9s pot replicar-se en pres\u00e8ncia de VHB, del qual el VHD pren prestades algunes de les seves estructures. En comparaci\u00f3 amb les persones que nom\u00e9s tenen infecci\u00f3 pel VHB, els que tenen una infecci\u00f3 cr\u00f2nica tant amb el VHB com amb el VHD tenen un risc molt major de desenvolupar malalties en forma de cirrosi i c\u00e0ncer de fetge. <em>\u201cEl VHD \u00e9s un contribuent significatiu a la malaltia hep\u00e0tica greu i al c\u00e0ncer de fetge\u201d<\/em>, indica la cient\u00edfica de IARC, Dra. Catherine de Martel. <em>\u201cEls resultats d\u2019aquest estudi informen el nostre treball sobre l\u2019associaci\u00f3 entre les infeccions virals i el c\u00e0ncer, que es centra en el desenvolupament de millors estrat\u00e8gies de prevenci\u00f3\u201d<\/em>.<\/p>\n<p>La professora Geretti conclou: <em>\u201cEl VHD ha estat descuidat durant molt de temps, perqu\u00e8 durant d\u00e8cades la prevalen\u00e7a d\u2019infecci\u00f3 va romandre incerta i faltava tractament efectiu. El mapeig de l\u2019epidemiologia de la infecci\u00f3 \u00e9s nom\u00e9s el primer pas. Es necessiten m\u00e9s esfor\u00e7os per reduir la c\u00e0rrega global de l\u2019hepatitis B cr\u00f2nica i desenvolupar medicaments que siguis segurs i efectius contra l\u2019hepatitis D i que siguin el suficientment assequibles per ser implementats a gran escala per aquells que m\u00e9s ho necessiten\u201d<\/em>.<\/p>\n<p>&nbsp;<\/p>\n<p>Font: <a href=\"https:\/\/www.who.int\/news-room\/detail\/29-04-2020-new-estimates-highlight-need-to-step-up-the-response-to-hepatitis-d\">who.int<\/a><\/p>\n<p>Refer\u00e8ncia: Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM (2020). The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. Published online 23 April 2020; <a href=\"https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008\">https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008<\/a><\/p>\n<p>Not\u00edcia tradu\u00efda per l\u2019ASSCAT<\/p>\n<p>[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=&#8221;Fila&#8221; custom_padding=&#8221;0px|||&#8221; _builder_version=&#8221;3.0.105&#8243; custom_margin=&#8221;|||&#8221;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_post_title admin_label=&#8221;Metadatos &#8211; Fecha \u00daltima actualizaci\u00f3n&#8221; title=&#8221;off&#8221; author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; categories=&#8221;off&#8221; comments=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;3.0.106&#8243; title_text_align=&#8221;left&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_align=&#8221;left&#8221; meta_font_size=&#8221;13px&#8221; meta_text_color=&#8221;#0082ca&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#cccccc&#8221; custom_margin=&#8221;50px|||&#8221; custom_padding=&#8221;10px|||&#8221; custom_css_before=&#8221;content:%22\u00daltima actualizaci\u00f3n:%22;&#8221; global_module=&#8221;3449&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243;][et_pb_sidebar orientation=&#8221;right&#8221; area=&#8221;et_pb_widget_area_8&#8243; module_class=&#8221;ac-posts-sidebar&#8221; _builder_version=&#8221;3.0.106&#8243; global_module=&#8221;3198&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_sidebar][\/et_pb_column][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;||0px|&#8221; prev_background_color=&#8221;#000000&#8243; module_class=&#8221;ac-post-section-share-rrss&#8221;][et_pb_row custom_padding=&#8221;||0px|&#8221; custom_margin=&#8221;|||&#8221; _builder_version=&#8221;3.0.105&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_divider color=&#8221;#e20611&#8243; show_divider=&#8221;on&#8221; divider_style=&#8221;ridge&#8221; _builder_version=&#8221;3.0.106&#8243; \/][et_pb_text _builder_version=&#8221;3.0.106&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#e20611&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||0px|&#8221; custom_padding=&#8221;|||&#8221; background_layout=&#8221;light&#8221; disabled=&#8221;on&#8221;]<\/p>\n<h5>Desde aqu\u00ed puedes compartir esta publicaci\u00f3n. \u00a1Gracias!<\/h5>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n<!-- Begin Yuzo --><div class='yuzo_related_post style-1'  data-version='5.12.77'><!-- without result --><div class='yuzo_clearfixed yuzo__title yuzo__title'><h3>Related Post<\/h3><\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/enginyeria-molecular-i-cel%c2%b7lular-eficac-per-via-intratumoral-contra-el-cancer\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/cima-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Enginyeria molecular i cel\u00b7lular efica\u00e7 per via in...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/retractament-de-lhepatitis-c-en-no-respondedors-als-medicaments-lliures-dinterfero-perspectiva-des-dels-estats-units\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/admin-ajax-150x150.png') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Retractament de l\u2019hepatitis C en no responde...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/la-poma-i-altres-sis-aliments-per-mantenir-els-teus-pulmons-sans\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/pulmones-150x150.jpeg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">La poma i altres sis aliments per mantenir els teu...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/els-organs-de-persones-portadores-del-virus-de-lhepatitis-c-actualment-son-valids-per-a-ser-trasplantats-experiencia-dels-estats-units\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/donacion-150x145.jpeg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Els \u00f2rgans de persones portadores del virus de l\u2019h...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n<\/div> <style>\n\t\t\t\t\t\t\t\t.yuzo_related_post img{width:120px !important; height:110px !important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{line-height:15px;background: !important;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover{background:#fcfcf4 !important; -webkit-transition: background 0.2s linear; -moz-transition: background 0.2s linear; -o-transition: background 0.2s linear; transition: background 0.2s linear;;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a{color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a:hover{ color:}!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover a{ color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{  margin: 0px  0px  0px  0px;   padding: 5px  5px  5px  5px;  }\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/style> <script>\n\t\t\t\t\t\t  jQuery(document).ready(function( $ ){\n\t\t\t\t\t\t\t\/\/jQuery('.yuzo_related_post').equalizer({ overflow : 'relatedthumb' });\n\t\t\t\t\t\t\tjQuery('.yuzo_related_post .yuzo_wraps').equalizer({ columns : '> div' });\n\t\t\t\t\t\t   })\n\t\t\t\t\t\t  <\/script> <!-- End Yuzo :) -->","protected":false},"excerpt":{"rendered":"<p>En un estudio publicat al Journal of Hepatology estimen que a tot el m\u00f3n, el virus de l\u2019hepatitis D (VHD) afecta a gaireb\u00e9 el 5% de les persones que tenen una infecci\u00f3 cr\u00f2nica amb el virus de l\u2019hepatitis B (VHB).<\/p>\n","protected":false},"author":9,"featured_media":15962,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","footnotes":""},"categories":[491],"tags":[6266,5355,6267,526,889,6268,4004,4059,535,3951,527],"class_list":["post-15960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-de-prensa-ca","tag-cancer-fetge-ca","tag-coinfeccio-vhd","tag-epidemiologia-mundial-ca","tag-hepatitis-b-ca","tag-hepatitis-d-ca","tag-iarc-ca","tag-journal-of-hepatology-ca","tag-malaltia-hepatica-ca","tag-oms-ca","tag-premsa-ca","tag-vhb-ca"],"_links":{"self":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/15960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/comments?post=15960"}],"version-history":[{"count":0,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/15960\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media\/15962"}],"wp:attachment":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media?parent=15960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/categories?post=15960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/tags?post=15960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}